


The Chemistry and Biology of Oligonucleotide Conjugates

R. L. JULIANO,* XIN MING, AND OSAMU NAKAGAWA[†]
*Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy,
University of North Carolina, Chapel Hill, North Carolina 27599, United States*

RECEIVED ON SEPTEMBER 12, 2011

CONSPECTUS



Short DNA or RNA oligonucleotides have tremendous potential as therapeutic agents. Because of their ability to engage in Watson–Crick base pairing, they can interact with mRNA or pre-mRNA targets with high selectivity. As a result, they could precisely manipulate gene expression. This possibility has engendered extensive efforts to develop oligonucleotides as drugs, and many candidates are already in clinical trials. However, a major impediment to the maturation of this field of oligonucleotide-based therapeutics remains: these relatively large and often highly charged molecules don't easily cross cellular membranes, making it difficult for them to reach their sites of action in the cytosol or nucleus.

In this Account, we summarize some basic features of the biology of antisense and siRNA oligonucleotides. We then discuss chemical conjugation as an approach to improving the intracellular delivery and therapeutic potential of these agents. Instead of focusing on the details of conjugation chemistry, we emphasize the pharmacological ramifications of oligonucleotide conjugates. In one important approach to improving delivery and efficacy, researchers have conjugated oligonucleotides with ligands designed to bind to particular receptors and thus provide specific interactions with cells. In another strategy, researchers have coupled antisense or siRNA with agents such as cell penetrating peptides that are designed to provoke escape of the conjugate from intracellular vesicular compartments. Although both of these strategies have had some success, further research is needed before oligonucleotide conjugates can find an important place in human therapeutics.

1. Basic Aspects of Oligonucleotide Biology

Classic Antisense Oligonucleotides. Relatively short (≥ 16 bases) oligonucleotides that are readily prepared by convenient solid phase synthesis can provide highly selective recognition among the multiple RNAs derived from the human genome. Upon introduction into cells, DNA antisense oligonucleotides can enter the nucleus and engage in specific base pairing with complementary sequences in

pre-mRNA. The formation of a DNA/RNA hybrid results in the recruitment of the enzyme RNaseH that can cleave the RNA, which then triggers further degradation of the cleaved fragments by other enzymatic processes (Figure 1). Native DNA, with phosphodiester internucleotide linkages, proved to be too unstable for work in cell culture or in vivo. Thus a large number of chemical modifications were developed to enhance the biological effectiveness of antisense




FIGURE 1. Oligonucleotide mechanisms of action. Four mechanisms are illustrated. In the nucleus: (i) classical antisense (ASO) mediated mRNA degradation via ribonuclease H; (ii) alteration of exon choice using splice switching oligonucleotides (SSO). In the cytosol: (iii) siRNA mediated mRNA degradation via the Ago 2/RISC complex; (iv) miRNA modulation of mRNA function.

molecules (Figure 2). A common modification is the substitution of sulfur for oxygen in the phosphate backbone leading to phosphorothioate (PS) oligonucleotides. These are considerably more stable than native DNA in the biological milieu; however, they have the potential disadvantage of being “sticky” and binding nonspecifically to proteins. Another important set of modifications involves substitution of aliphatic residues at the 2' position of the nucleoside sugar thus creating 2'-O-methyl and similar derivatives. This results in molecules that are more RNA-like and often bind with higher affinity to RNA. Another important modification is represented by locked nucleic acids (LNAs) where a 2'–4' bridge results in oligonucleotides with very high binding affinity. Finally, families of uncharged oligonucleotides have been created by radical modification of the backbone. Replacement of the phosphodiester backbone with peptide linkages gives rise to peptide nucleic acids (PNAs), while inclusion of nonionic phosphorodiamidate linkages gives rise to morpholino oligonucleotides. These backbone modified molecules, as well as the 2' modifications, do not recruit RNase H but do retain excellent base pairing specificity and the ability to influence other processes involving mRNA such as message splicing and protein translation.^{1,2}

siRNA and miRNA. A surge of recent discoveries have fundamentally altered our understanding of the role of RNA in the cell. Not only is mRNA the key link between the genome and proteome, but multiple other forms of RNA are now known to play critical roles in virtually all aspects of gene expression.³ From the therapeutic perspective siRNA

and miRNA have evoked the greatest interest. Short (~21 base pair) double stranded RNA segments can be loaded onto the multiprotein RISC complex.⁴ For siRNA action the Argonaute 2 (Ago 2) protein is the critical element of the RISC complex; this protein degrades one of the two strands (sense strand) while retaining the other (the antisense or guide strand). The loaded RISC complex then surveys mRNAs in the cytosol and selects for perfect complementarity. The mRNA in the RNA/RNA duplex is then cut at a position 10 bases from the 5' end of the guide strand, and the two fragments of the mRNA are then further degraded by other enzymatic processes. See Figure 1. The actions of miRNAs are also mediated by the RISC complex but in this case there is usually not full complementarity between the guide strand and the target mRNA and the binding sites are often in the 3' untranslated region of the message.⁵ See Figure 1. This results in message sequestration into P-bodies,⁶ interruption of translation, and often in degradation. Since only partial complementarity is needed, this means that a single miRNA may interact with multiple mRNAs and thus be involved in the regulation of multiple genes. While in some cases miRNAs themselves have been used to modify expression of disease-related genes,⁷ a more common approach is the use of “antagomirs”, antisense oligonucleotides complementary to the miRNA that can bind and inactivate it.⁸

Splice Switching Oligonucleotides. An important approach involves the use of so-called “splice switching antisense oligonucleotides” (SSOs). Although the human genome contains only about 20 000 genes, it can direct




FIGURE 2. Common chemical modifications of oligonucleotides. Other than the morpholino and PNA backbone modifications that form uncharged molecules, the various chemistries shown can be applied to siRNA as well as to single stranded oligonucleotides.

the production of hundreds of thousands of proteins via alternative splicing of pre-mRNA. Using oligonucleotides complementary to splice junctions, it is possible to redirect the nuclear splicing machinery to include or exclude particular exons (or segments of introns).⁹ See Figure 1. The SSO must be designed so that it does not recruit RNaseH or the result would be degradation rather than altered splicing. Fortunately, this is easy to do using either oligonucleotides that are fully substituted at the 2' position, or that have uncharged backbones. The SSO technology will hopefully be useful in the many human diseases that involve defects in splicing; additionally, through manipulation of the splicing of reporter genes, it has provided a very convenient assay for measuring the effectiveness of delivery of oligonucleotides to the nucleus.¹⁰

Off-Target Effects. In theory, antisense, siRNA, and SSO oligonucleotides should be capable of modulating the

expression of only the target gene and no other gene. However, in practice there are several sources of off-target effects of oligonucleotides. Simplest to understand are situations where there is partial complementarity between the target message and another message. Another source of off-target effects relates particularly to phosphorothioate oligonucleotides that tend to bind nonspecifically to many proteins. In addition, any single-stranded oligonucleotide can fold to form a three-dimensional structure that can act as an aptamer¹¹ and thus serve as a ligand for proteins. Finally, many types of oligonucleotides interact with toll-like receptors (TLRs) or other components of the innate immune system¹² to trigger the expression of cytokines and other genes involved in host defense mechanisms.

Pharmacokinetics and Biodistribution of Oligonucleotides. There is a vast literature on this topic including excellent recent reviews;^{13,14} however, the essence can be




FIGURE 3. Pathways of endocytosis and intracellular trafficking. Several of the illustrated endocytotic pathways have been associated with the uptake of various types of oligonucleotide conjugates or of “free” oligonucleotides. Various intracellular membranous organelles are also illustrated as are some of the proteins associated with trafficking pathways. The Rab proteins are GTPases that help to guide intracellular traffic. (Reproduced with permission from ref 23. Copyright XXXX American Chemical Society.)

described rather briefly. Systemically injected oligonucleotides rapidly (minutes) leave the blood compartment and are redistributed to various tissues.^{15,16} Since the molecular mass of most oligonucleotides is well below the cutoff for renal filtration, there is a second phase of clearance (minutes-hours) when the oligonucleotides exit from tissue stores and are excreted in the urine. An exception to this is the case of phosphorothioates, since they tend to bind to plasma and tissue proteins thus substantially prolonging their lifetime in the body.¹⁴ While systemically administered oligonucleotides can enter most tissues to some degree (other than the CNS), both antisense and siRNAs tend to be most highly accumulated in tissues that are rich in reticuloendothelial cells including the liver and spleen, or in kidney proximal tubule cells.^{13,17} This natural biodistribution has influenced the choice of therapeutic targets for oligonucleotide pharmacology.

Cellular Uptake and Subcellular Trafficking of Oligonucleotides. Being large, polar molecules oligonucleotides do not permeate across biological membranes. In general oligonucleotides enter cells by some form of endocytosis and then traffic to diverse subcellular compartments. Recently, the complexity of oligonucleotide uptake and intracellular trafficking and its role in determining the functional effectiveness of these molecules has become better appreciated.^{10,18–21} As depicted in Figure 3, there are multiple mechanisms of endocytosis leading to distinct intracellular membrane-bound compartments including early and

late endosomes, lysosomes, the Golgi apparatus, and the endoplasmic reticulum.²² Much of the oligonucleotide that accumulates in cells becomes nonproductively trapped in endomembrane compartments. However, because of the dynamic nature of intracellular trafficking processes, a small amount of oligonucleotide can “leak” to the cytosol and diffuse into the nucleus.²³ It is this minor component of the total cellular pool that is pharmacologically active. In general, phosphorothioate-based antisense molecules are taken up more effectively than either siRNA or uncharged single-strand oligonucleotides; however, even the phosphorothioates are subject to endosome trapping.

Clinical Evaluation of Oligonucleotides. There has been an enormous effort to mature oligonucleotide pharmacology to the point of human application with numerous ongoing clinical trials of both antisense and siRNA.^{13,24} In most cases, oligonucleotides in current studies in humans are given as “free” molecules, not associated with any sort of carrier or delivery system. However, a few trials involved use of lipid-based delivery systems. The oligonucleotides being tested clinically mainly incorporate relatively simple chemical modifications such as use of 2'-O-methoxyethyl residues in antisense or F or 2'-O-methyl modifications of siRNA. Many of the intended targets are cancer-related; however, there are also examples of trials that focus on local administration such as inhalation,²⁵ or on targets in the liver,²⁶ an organ that tends to accumulate oligonucleotides. A very exciting development is the testing of both morpholino²⁷

and 2'-*O*-methyl²⁸ SSOs to correct (at the RNA level) the genetic defect in Duchenne muscular dystrophy, an otherwise incurable disease.

Key Challenges for Oligonucleotide Pharmacology. Despite some promising clinical developments with “free” antisense or siRNA molecules, there remain concerns about the inability of these compounds to permeate membranes, their unproductive accumulation in endosomes, and their poor pharmacokinetic and biodistribution profiles.^{16,29} Additionally, it would be highly desirable to be able to “target” oligonucleotides to specific cells or tissues and thus enhance their selective therapeutic actions. Much work has been devoted to addressing these challenges with the major thrusts being the development of lipid based or polymer based nanocarrier systems as summarized in recent reviews.^{30,31} In this Account, however, we will focus solely on molecularly defined chemical conjugates as an alternative strategy for overcoming the challenges of oligonucleotide pharmacology.

2. Chemical Conjugation of Oligonucleotides

Much of the work on chemical modification of oligonucleotides has been directed at increasing stability in the biological milieu, improving potency, and reducing off-target effects.^{1,2} More directly related to this Account is the chemistry underlying conjugation of oligonucleotides with molecules designed to improve intracellular delivery or in vivo pharmacokinetics and biodistribution.³² An excellent recent review delineates many of the issues involved in the conjugation of oligonucleotides with various partners.³³ For example, the merits of solid phase versus solution phase conjugation are discussed. The former is highly efficient and facilitates purification; however, it is limited by the availability of appropriate synthons and by the need for both partners of the conjugate to be stable under the conditions of synthesis. In contrast, solution phase conjugation allows synthesis of each component under the most appropriate conditions, but the conjugation reaction may be inefficient and substantial purification problems can occur. This review also discusses specific aspects of the conjugation of oligonucleotides with peptides, carbohydrates, and lipophilic molecules. Another useful review focuses entirely on solid phase synthesis of oligonucleotide conjugates.³⁴ Recent reports have brought new conjugation strategies to bear; this includes use of “click chemistry”^{35,36} and conjugation via phosphoramidation reactions.³⁷

Peptides. Perhaps the most extensive studies on peptide–oligonucleotide conjugation have been done in the context

of PNA and morpholino SSOs.^{38,39} While it is possible to produce peptide/PNA chimeras by solid phase synthesis, in most cases peptide–oligonucleotide conjugates are formed by solution phase conjugation of the peptide to the oligonucleotide followed by purification. A variety of linkages have been used including amide, thioether, thiol-maleimide, ester, and disulfide. Conjugates of peptides with noncharged oligonucleotides are purified by reversed phase HPLC while conjugates with charged oligonucleotides are usually purified by ion exchange or by large scale PAGE. In our hands, we have found that analysis by MALDI-TOF mass spectrometry is suitable for many peptide–oligonucleotide conjugates but that some of the larger conjugates require use of electrospray ionization mass analysis. An important question is whether it is essential to use a bioreversible linkage such as a disulfide in order to attain biological activity. This does not seem to be the case, however, and experience in our laboratory^{40,41} as well as by others⁴² has shown that both bioreversible and nonreversible linkages can work well.

Lipids. The addition of lipophilic moieties to antisense and especially siRNA has proven to be a powerful approach to modification of the pharmacokinetic and pharmacodynamic characteristics of oligonucleotides. In particular, conjugation with cholesterol promotes the interaction of the oligonucleotide with albumin and serum lipoproteins and subsequently promotes tissue uptake primarily via the hepatic lipoprotein receptors.⁴³ Tocopherol (vitamin E) conjugates have also been used in a similar context.⁴⁴ In general, simple lipophilic groups can be incorporated via solid phase synthesis using the appropriate phosphoramidites, some of which are commercially available. Chemical aspects of lipid conjugation to oligonucleotides as well as the physical properties of such conjugates have been extensively discussed in a recent review.⁴⁵

Carbohydrates. Conjugation of oligonucleotides with carbohydrate moieties can provide a powerful approach to targeting the lectin-like proteins that exist on many cell types. While linking a monosaccharide to an oligonucleotide is relatively simple and can be approached through the preparation of carbohydrate containing phosphoramidites, synthesis of oligonucleotides bearing the more complex oligosaccharide structures needed for optimal lectin recognition is far more challenging.³⁴ Recently, “click” chemistry has been applied to the preparation of several types of oligonucleotide glycoconjugates including rather complicated branched oligosaccharides.^{46,47}




FIGURE 4. In vivo effects of a targeted oligonucleotide conjugate. A RGD–SSO conjugate was used in these experiments. Human A375 melanoma cells were stably transfected with a luciferase reporter cassette that responds to an appropriate SSO by increasing production of properly spliced luciferase message and functional luciferase protein. The cells were then used as xenografts in SCID mice. After the tumors were established, the animals were treated with 10 mg/kg of RGD-SSO or unconjugated SSO or with saline. Three days later, luciferin was injected and photon emission due to luciferase was measured on an optical imaging system. Induction of luciferase was approximately 3-fold stronger in the animals treated with RGS–SSO as compared to free SSO, while treatment with saline had no effect.

Nucleic Acids. The formation of conjugates or chimeras of antisense or siRNA oligonucleotide with other nucleic acids moieties has some very interesting ramifications. One approach has been to prepare chimeras of siRNA with aptamers that target specific cell surface receptors. Typically a polynucleotide comprising the “passenger” (sense) strand of the siRNA linked to the aptamer is synthesized by in vitro transcription, including the incorporation of 2'-F

pyrimidines; thereafter the “guide” (antisense) stand is complexed by hybridization.^{48,49}

3. Receptor Targeted Conjugates

Lately there has been a substantial increase in work on receptor targeting of oligonucleotides via conjugation.^{50,19} For example, our laboratory has described Arg-Gly-Asp (RGD) peptide conjugates of splice switching antisense

TABLE 1. Selected Examples of Biologically Active Oligonucleotide Conjugates

oligonucleotide	conjugation partner	linkage	target	cell uptake via	ref
2'-O-Me PS SSO	bombesin peptide	maleimide terminated peptide linked to 5' SH oligonucleotide	abnormal exon in luciferase reporter	BB2 receptor	10
2'-F modified siRNA	none: chimera with RNA aptamer made by in vitro transcription	NA	Plk-1 mRNA	PSMA	48
siRNA	CpG DNA oligonucleotide	carbon linker between the CpG and antisense siRNA strand	stat 3 mRNA	TLR-9	53
morpholino SSO	novel CPP with 6-aminohexanoic acids and arginines	amide linker	exon and intron 23 of the mouse dystrophin gene	CPP mediated nonspecific uptake	64
siRNA	tocopherol	5' phosphate linkage using a tocopherol phosphoramidite	ApoB mRNA	lipoprotein receptors?	44

oligonucleotides (SSOs) that can be effectively delivered to melanoma cells in culture via the $\alpha v\beta 3$ integrin.⁴⁰ The RGD–SSO conjugates have also been tested to a limited degree in xenograft models of melanoma and have shown some activity (Figure 4). We have also studied conjugates of SSOs to bombesin, a peptide that binds with high affinity to BB2, a G protein-coupled receptor that is overexpressed in some tumors including prostate cancer¹⁰ (Table 1) and have demonstrated substantial receptor-dependent effects in this system. We have also used anisamide, a high affinity small molecule ligand for the sigma receptor, to target oligonucleotides selectively to tumor cells. The anisamide–SSO conjugates were prepared by a novel solid phase method that involves creation of phosphoramidites of the ligand.⁵¹ We have recently extended the RGD targeting approach to siRNA. Thus bi-, tri-, and tetravalent RGD conjugates of a potent luciferase siRNA were synthesized.⁵² As compared to unconjugated siRNA, each of the RGD conjugates displayed a remarkably increased and highly receptor-selective uptake into M21 melanoma cells that express the $\alpha v\beta 3$ integrin. Interestingly, however, only the tri- and tetravalent conjugates displayed significant “knockdown” effects. The issue of valency is a complex one in the context of conjugates between oligonucleotides and high affinity ligands. Initially, we had assumed that increasing valency would lead to increased avidity and thus increased cell uptake and biological effect. However, in our experience, this simple pattern does not necessarily prevail. For example, increasing valency does not necessarily lead to increased cell uptake. We have found this both with RGD–siRNA conjugates⁵² and with bombesin–SSO conjugates (unpublished). However, in

the case of the RGD–siRNA conjugates, there was an increased biological effect of the higher valency conjugates even though uptake levels were similar. We hypothesize that this behavior may be based on different intracellular trafficking of the various conjugates. Recently, evidence has been accumulating that the route of intracellular trafficking can profoundly influence the pharmacological activity of oligonucleotides.^{18,21}

As mentioned above, there has been considerable recent interest in using nucleic acid conjugates or chimeras for the targeting of siRNA (Table 1). One example involves the delivery of siRNA by targeting TLRs.⁵³ An unmethylated CpG DNA oligonucleotide known to bind to TLR9 was chemically conjugated to a siRNA. This resulted in enhanced “knockdown” of endogenous and reporter genes in immune system cells known to express TLR9. In in vivo studies, a CpG siRNA targeting the immunosuppressive regulator Stat3 resulted in enhanced antitumor immune responses. A very promising approach to selective delivery of oligonucleotides involves use of nucleic acid aptamers.¹¹ A pioneering report described the biological effects of chimeric molecules comprised an aptamer with high affinity for the prostate specific membrane antigen (PMSA) surface glycoprotein linked to siRNAs that affected key survival genes including *Plk1* and *Bcl2*.⁵⁴ In cell culture, the aptamer–siRNA chimeras were taken up efficiently by cells that expressed PSMA and they effectively reduced the target mRNAs. When administered by direct intratumoral injection, the chimeras produced a significant tumor growth inhibition. A chemically optimized version of a PSMA aptamer–*Plk1* siRNA chimera displayed antitumor activity against PMSA-expressing tumors when

given by systemic administration.⁴⁸ Other important examples of aptamer–siRNA chimeras are also beginning to emerge. Thus, an aptamer siRNA chimera that bound to the viral gp120 protein was able to substantially reduce viral loads in HIV infected humanized mice.⁴⁹ Similarly, an aptamer targeting the T-cell CD4 receptor linked to antiviral siRNAs was able to protect against vaginal HIV transmission in humanized mice.⁵⁵ In another study, PSMA–siRNA chimeras inhibited tumor growth in vivo using siRNAs directed against *Upf2* and *Smg1*, two genes involved in nonsense mediated mRNA decay and thus in immune regulation of tumors.⁵⁶

The various studies discussed above, using receptor-targeted conjugates of antisense or siRNA, strongly suggest that monomeric ligand–oligonucleotide conjugates can produce significant biological effects both in cell culture and in vivo without the use of any transfection agents. In many cases, strong pharmacological effects can be attained at nanomolar levels of targeted SSO or siRNA. Despite these promising early studies, there are several issues that must be addressed to allow further progress. A major impediment is the dearth of knowledge about the uptake and trafficking mechanisms involved in receptor mediated oligonucleotide delivery. Additionally, many synthetic challenges remain. While it is relatively easy to make monovalent peptide–oligonucleotide conjugates, more complex conjugations are much more demanding. Thus, conjugates incorporating large nucleic acid aptamers, or multivalent peptide ligands, can be challenging to synthesize and hard to purify.

4. Conjugates with Cell Penetrating Peptides

Cell penetrating peptides (CPPs) are peptides, usually cationic, that purportedly possess the ability to cross membranes and also to convey attached “cargos” such as other peptides, proteins, or nucleic acids across the membrane as well. The TAT and Antennepedia peptides are early examples of CPPs, but a large variety of new CPPs have been described more recently.^{57,58} Initially, it was believed CPPs or CPP–cargo conjugates could directly translocate across the plasma membrane. However, this view has been radically revised and most studies suggest that cationic CPPs initially bind to negatively charged proteoglycans at the cell surface, are subsequently internalized into endosomes, and may then escape from endosomes to enter the cytosol. An important consideration is that the nature of the attached cargo plays a major role in CPP uptake mechanisms and in the effectiveness of cytosolic delivery; as might be anticipated, smaller cargos are more effectively delivered to the cytosol

while larger moieties are primarily retained within endosomes.^{59,60}

Although there have been numerous studies of both chemical conjugates and noncovalent complexes of antisense and siRNA with CPPs, the utilization of CPPs for intracellular delivery of oligonucleotides has had a somewhat checkered history.^{38,50} In general, the conjugation of CPPs with charged oligonucleotides has not led to effective compounds. One issue is the tendency of the positively charged CPPs and the anionic oligonucleotides to aggregate and form insoluble complexes. However, conjugation with uncharged oligonucleotides such as morpholinos or PNAs has been more promising. Thus, studies with conjugates of novel CPPs to PNA⁶¹ or morpholino⁶² SSOs have shown excellent splice-correction activity in cell culture, and promising therapeutic performance in mouse models of Duchenne muscular dystrophy (Table 1).^{63,64} An interesting approach involves synthesizing CPP–oligonucleotide conjugates that also contain a lipid moiety;⁶⁵ this seems to lead to enhanced endosomal escape and thus greater efficacy of the conjugated PNA SSO. A parallel approach has been to create nanoparticle complexes of anionic oligonucleotides and cationic CPPs; this strategy has been recently reviewed in detail,⁶⁶ but is really outside of the scope of the current Account and will not be further discussed. A potential limitation with CPP–SSO conjugates is that, as with unconjugated SSOs, they usually require micromolar concentrations (or the in vivo equivalent) to attain significant biological effects. This may indicate that CPPs are only partially effective in releasing endosomal stores of oligonucleotides. As mentioned previously, SSOs are being evaluated clinically;^{27,28} hopefully the further development of novel, nontoxic CPP–SSO conjugates may provide enhanced therapeutic effects.

5. Conclusions

While chemical modification has been an important part of the entire history of oligonucleotide research, the subtopic of oligonucleotide conjugation has become particularly active recently. New strategies such as “click chemistry” and various solid-state approaches have made conjugation with complex partners more accessible. The field is developing experience with the conjugation of a variety of moieties including peptides, lipids, carbohydrates and other forms of nucleic acids, and the biological ramifications of various types of conjugates are becoming better understood. A somewhat surprising generalization is that the linker between oligonucleotide and its partner moiety can be quite varied with relatively little impact on the biological potency

of the conjugate (although exceptions will no doubt occur). Coupling to ligands that bind selectively to cellular receptors seems a very promising approach for both single stranded oligonucleotides and siRNA. Impressive successes in cell culture and in vivo have been attained with nucleic acid aptamers as ligands, while peptide–oligonucleotide conjugates also have demonstrated potency and specificity. Reports on the biological properties of lipid and carbohydrate conjugates have not been as abundant in the published literature, but there is certainly a good deal of activity concerning these approaches. Cell penetrating peptides have found an important niche in the delivery of uncharged oligonucleotides, primarily of the SSO type that have such great potential in the treatment of genetic diseases. Further developments in the chemistry of CPPs should augment their potential as delivery agents. An interesting concept is whether some of the beneficial properties of receptor-targeted ligands and of CPPs could be combined in the same oligonucleotide conjugate thus improving both cellular specificity and intracellular delivery.

This work was supported by NIH Grant RO1 CA151964 to R.L.J. The authors wish to thank Ben Parise for expert assistance with graphics.

FOOTNOTES

*To whom correspondence should be addressed. E-mail: arjay@med.unc.edu.

The authors declare no competing financial interest.

[†]Osaka University of Pharmaceutical Sciences 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan.

REFERENCES

- Corey, D. R. RNA learns from antisense. *Nat. Chem. Biol.* **2007**, *3*, 8–11.
- Kurreck, J. RNA interference: from basic research to therapeutic applications. *Angew. Chem.* **2009**, *48*, 1378–1398.
- Mozazed, D. Small RNAs in transcriptional gene silencing and genome defence. *Nature* **2009**, *457*, 413–420.
- Elbashir, S. M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* **2001**, *411*, 494–498.
- Djuranovic, S.; Nahvi, A.; Green, R. A parsimonious model for gene regulation by miRNAs. *Science* **2011**, *331*, 550–553.
- Eulalio, A.; Behm-Ansmant, I.; Izaurralde, E. P bodies: at the crossroads of post-transcriptional pathways. *Nat. Rev. Mol. Cell Biol.* **2007**, *8*, 9–22.
- Rosbach, M. Small non-coding RNAs as novel therapeutics. *Curr. Mol. Med.* **2010**, *10*, 361–368.
- Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K. G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with “antagomirs”. *Nature* **2005**, *438*, 685–689.
- Sazani, P.; Kole, R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. *J. Clin. Invest.* **2003**, *112*, 481–486.
- Ming, X.; Alam, M. R.; Fisher, M.; Yan, Y.; Chen, X.; Juliano, R. L. Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor. *Nucleic Acids Res.* **2010**, *38*, 6567–76.
- Thiel, K. W.; Giangrande, P. H. Therapeutic applications of DNA and RNA aptamers. *Oligonucleotides* **2009**, *19*, 209–222.
- Miyake, K. Nucleic acid-sensing Toll-like receptors: beyond ligand search. *Adv. Drug Delivery Rev.* **2008**, *60*, 782–785.
- Bennett, C. F.; Swayze, E. E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. *Annu. Rev. Pharmacol. Toxicol.* **2010**, *50*, 259–293.
- Geary, R. S. Antisense oligonucleotide pharmacokinetics and metabolism. *Expert Opin. Drug Metab. Toxicol.* **2009**, *5*, 381–391.
- Yamamoto, T.; Nakatani, M.; Narukawa, K.; Obika, S. Antisense drug discovery and development. *Future Med. Chem.* **2011**, *3*, 339–365.
- Juliano, R.; Bauman, J.; Kang, H.; Ming, X. Biological barriers to therapy with antisense and siRNA oligonucleotides. *Mol. Pharmaceutics* **2009**, *6*, 686–695.
- Molitoris, B. A.; Dagher, P. C.; Sandoval, R. M.; Campos, S. B.; Ashush, H.; Fridman, E.; Brafman, A.; Faerman, A.; Atkinson, S. J.; Thompson, J. D.; Kalinski, H.; Skalter, R.; Erlich, S.; Feinstein, E. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. *J. Am. Soc. Nephrol.* **2009**, *20*, 1754–1764.
- Alam, M. R.; Ming, X.; Dixit, V.; Fisher, M.; Chen, X.; Juliano, R. L. The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. *Oligonucleotides* **2010**, *20*, 103–109.
- Ming, X. Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis. *Expert Opin. Drug Delivery* **2011**, *8*, 435–449.
- Ming, X.; Sato, K.; Juliano, R. L. Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes. *J. Controlled Release* **2011**, *153*, 83–92.
- Koller, E.; Vincent, T. M.; Chappell, A.; De, S.; Manoharan, M.; Bennett, C. F. Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. *Nucleic Acids Res.* **2011**, *39*, 4795–4807.
- Doherty, G. J.; McMahon, H. T. Mechanisms of endocytosis. *Annu. Rev. Biochem.* **2009**, *78*, 857–902.
- Juliano, R. L.; Ming, X.; Nakagawa, O. Cellular Uptake and Intracellular Trafficking of Antisense and siRNA Oligonucleotides. *Bioconjugate Chem.* **2011**, *23*, 147–157.
- Vaishnav, A. K.; Gollub, J.; Gamba-Vitalo, C.; Hutabarat, R.; Sah, D.; Meyers, R.; de Fougerolles, T.; Maraganore, J. A status report on RNAi therapeutics. *Silence* **2010**, *1*, 14.
- Zamora, M. R.; Budev, M.; Rolfe, M.; Gottlieb, J.; Humar, A.; Devincenzo, J.; Vaishnav, A.; Cehelsky, J.; Albert, G.; Nochur, S.; Gollub, J. A.; Glanville, A. R. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. *Am. J. Respir. Crit. Care Med.* **2011**, *183*, 531–538.
- Bell, D. A.; Hooper, A. J.; Burnett, J. R. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. *Expert Opin. Invest. Drugs* **2011**, *20*, 265–272.
- Cirak, S.; Arechavala-Gomez, V.; Guglieri, M.; Feng, L.; Torelli, S.; Anthony, K.; Abbs, S.; Garraza, M. E.; Bourke, J.; Wells, D. J.; Dickson, G.; Wood, M. J.; Wilton, S. D.; Straub, V.; Kole, R.; Shrewsbury, S. B.; Sewry, C.; Morgan, J. E.; Bushby, K.; Muntoni, F. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. *Lancet* **2011**, *378*, 595–605.
- Hammond, S. M.; Wood, M. J. PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy. *Curr. Opin. Mol. Ther.* **2010**, *12*, 478–486.
- Whitehead, K. A.; Langer, R.; Anderson, D. G. Knocking down barriers: advances in siRNA delivery. *Nat. Rev. Drug Discovery* **2009**, *8*, 129–138.
- Tseng, Y. C.; Mozumdar, S.; Huang, L. Lipid-based systemic delivery of siRNA. *Adv. Drug Delivery Rev.* **2009**, *61*, 721–731.
- Tamura, A.; Nagasaki, Y. Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles. *Nanomedicine (London, U.K.)* **2010**, *5*, 1089–1102.
- Marlin, F.; Simon, P.; Saison-Behmoaras, T.; Giovannangeli, C. Delivery of oligonucleotides and analogues: the oligonucleotide conjugate-based approach. *ChemBioChem* **2010**, *11*, 1493–1500.
- Singh, Y.; Murat, P.; Defranco, E. Recent developments in oligonucleotide conjugation. *Chem. Soc. Rev.* **2010**, *39*, 2054–2070.
- Lonnberg, H. Solid-phase synthesis of oligonucleotide conjugates useful for delivery and targeting of potential nucleic acid therapeutics. *Bioconjugate Chem.* **2009**, *20*, 1065–1094.
- Meyer, A.; Spinelli, N.; Dumy, P.; Vasseur, J. J.; Morvan, F.; Defranco, E. Oligonucleotide sequential bis-conjugation via click-oxime and click-Huisgen procedures. *J. Org. Chem.* **2010**, *75*, 3927–3930.
- Yamada, T.; Peng, C. G.; Matsuda, S.; Addepalli, H.; Jayaprakash, K. N.; Alam, M. R.; Mills, K.; Maier, M. A.; Charisse, K.; Sekine, M.; Manoharan, M.; Rajeev, K. G. Versatile site-specific conjugation of small molecules to siRNA using click chemistry. *J. Org. Chem.* **2011**, *76*, 1198–1211.
- Wang, T. P.; Chiou, Y. J.; Chen, Y.; Wang, E. C.; Hwang, L. C.; Chen, B. H.; Chen, Y. H.; Ko, C. H. Versatile phosphoramidation reactions for nucleic acid conjugations with peptides, proteins, chromophores, and biotin derivatives. *Bioconjugate Chem.* **2010**, *21*, 1642–1655.
- Lebleu, B.; Moulton, H. M.; Abes, R.; Ivanova, G. D.; Abes, S.; Stein, D. A.; Iversen, P. L.; Arzumanov, A. A.; Gait, M. J. Cell penetrating peptide conjugates of steric block oligonucleotides. *Adv. Drug Delivery Rev.* **2008**, *60*, 517–529.

- 39 Said Hassane, F.; Saleh, A. F.; Abes, R.; Gait, M. J.; Lebleu, B. Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. *Cell. Mol. Life Sci.* **2010**, *67*, 715–726.
- 40 Alam, M. R.; Dixit, V.; Kang, H.; Li, Z. B.; Chen, X.; Trejo, J.; Fisher, M.; Juliano, R. L. Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. *Nucleic Acids Res.* **2008**, *36*, 2764–2776.
- 41 Astriab-Fisher, A.; Sergueev, D.; Fisher, M.; Shaw, B. R.; Juliano, R. L. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions. *Pharm. Res.* **2002**, *19*, 744–754.
- 42 Turner, J. J.; Arzumanov, A. A.; Gait, M. J. Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides. *Nucleic Acids Res.* **2005**, *33*, 27–42.
- 43 Wolfrum, C.; Shi, S.; Jayaprakash, K. N.; Jayaraman, M.; Wang, G.; Pandey, R. K.; Rajeev, K. G.; Nakayama, T.; Charise, K.; Ndungo, E. M.; Zimmermann, T.; Koteliansky, V.; Manoharan, M.; Stoffel, M. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. *Nat. Biotechnol.* **2007**, *25*, 1149–1157.
- 44 Nishina, K.; Unno, T.; Uno, Y.; Kubodera, T.; Kanouchi, T.; Mizusawa, H.; Yokota, T. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. *Mol. Ther.* **2008**, *16*, 734–740.
- 45 Patwa, A.; Gissot, A.; Bestel, I.; Barthelemy, P. Hybrid lipid oligonucleotide conjugates: synthesis, self-assemblies and biomedical applications. *Chem Soc Rev* **2011**, *40*, 5844–5854.
- 46 Kiviniemi, A.; Virta, P.; Drenichev, M. S.; Mikhailov, S. N.; Lonnberg, H. Solid-Supported 2'-O-Glycoconjugation of Oligonucleotides by Azidation and Click Reactions. *Bioconjugate Chem.* **2011**, *22*, 1249–1255.
- 47 Pourceau, G.; Meyer, A.; Vasseur, J. J.; Morvan, F. Synthesis of a Glycomimetic Oligonucleotide Conjugate by 1,3-Dipolar Cycloaddition. *Methods Mol. Biol.* **2011**, *751*, 167–193.
- 48 Dassie, J. P.; Liu, X. Y.; Thomas, G. S.; Whitaker, R. M.; Thiel, K. W.; Stockdale, K. R.; Meyerholz, D. K.; McCaffrey, A. P.; McNamara, J. O., 2nd; Giangrande, P. H. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. *Nat. Biotechnol.* **2009**, *27*, 839–849.
- 49 Neff, C. P.; Zhou, J.; Remling, L.; Kuruvilla, J.; Zhang, J.; Li, H.; Smith, D. D.; Swiderski, P.; Rossi, J. J.; Akkina, R. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. *Sci. Transl. Med.* **2011**, *3*, 66ra6.
- 50 Juliano, R.; Alam, M. R.; Dixit, V.; Kang, H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. *Nucleic Acids Res.* **2008**, *36*, 4158–4171.
- 51 Nakagawa, O.; Ming, X.; Huang, L.; Juliano, R. L. Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. *J. Am. Chem. Soc.* **2010**, *132*, 8848–8849.
- 52 Alam, M. R.; Ming, X.; Fisher, M.; Lackey, J. G.; Rajeev, K. G.; Manoharan, M.; Juliano, R. L. Multivalent Cyclic RGD Conjugates for Targeted Delivery of Small Interfering RNA. *Bioconjugate Chem.* **2011**, *22*, 1673–1681.
- 53 Kortylewski, M.; Swiderski, P.; Herrmann, A.; Wang, L.; Kowolik, C.; Kujawski, M.; Lee, H.; Scuto, A.; Liu, Y.; Yang, C.; Deng, J.; Soifer, H. S.; Raubitschek, A.; Forman, S.; Rossi, J. J.; Pardoll, D. M.; Jove, R.; Yu, H. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. *Nat. Biotechnol.* **2009**, *27*, 925–932.
- 54 McNamara, J. O., 2nd; Andrechek, E. R.; Wang, Y.; Viles, K. D.; Rempel, R. E.; Gilboa, E.; Sullenger, B. A.; Giangrande, P. H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. *Nat. Biotechnol.* **2006**, *24*, 1005–1015.
- 55 Wheeler, L. A.; Trifonova, R.; Vrbanc, V.; Basar, E.; McKernan, S.; Xu, Z.; Seung, E.; Deruaz, M.; Dudek, T.; Einarsson, J. I.; Yang, L.; Allen, T. M.; Luster, A. D.; Tager, A. M.; Dykxhoorn, D. M.; Lieberman, J. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. *J. Clin. Invest.* **2011**, *121*, 2401–2412.
- 56 Pastor, F.; Kolonias, D.; Giangrande, P. H.; Gilboa, E. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. *Nature* **2010**, *465*, 227–230.
- 57 Lindgren, M.; Langel, U. Classes and prediction of cell-penetrating peptides. *Methods Mol. Biol.* **2011**, *683*, 3–19.
- 58 Juliano, R. L.; Alam, R.; Dixit, V.; Kang, H. M. Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents. *Wiley Interdiscip. Rev.: Nanomed. Nanobio-technol.* **2009**, *1*, 324–335.
- 59 El-Andaloussi, S.; Jarver, P.; Johansson, H. J.; Langel, U. Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. *Biochem. J.* **2007**, *407*, 285–292.
- 60 Tunneemann, G.; Martin, R. M.; Haupt, S.; Patsch, C.; Edenhofer, F.; Cardoso, M. C. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. *FASEB J.* **2006**, *20*, 1775–1784.
- 61 Ivanova, G. D.; Arzumanov, A.; Abes, R.; Yin, H.; Wood, M. J.; Lebleu, B.; Gait, M. J. Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. *Nucleic Acids Res.* **2008**, *36*, 6418–6428.
- 62 Abes, R.; Moulton, H. M.; Clair, P.; Yang, S. T.; Abes, S.; Melikov, K.; Prevot, P.; Youngblood, D. S.; Iversen, P. L.; Chemomordik, L. V.; Lebleu, B. Delivery of steric block morpholino oligomers by (R-X-R)₄ peptides: structure-activity studies. *Nucleic Acids Res.* **2008**, *36*, 6343–6354.
- 63 Yin, H.; Saleh, A. F.; Betts, C.; Camelliti, P.; Seow, Y.; Ashraf, S.; Arzumanov, A.; Hammond, S.; Merritt, T.; Gait, M. J.; Wood, M. J. Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-mediated Dystrophin Exon Skipping in Heart and Phenotypic Correction in mdx Mice. *Mol. Ther.* **2011**, *19*, 1295–1303.
- 64 Goyenvall, A.; Babbs, A.; Powell, D.; Kole, R.; Fletcher, S.; Wilton, S. D.; Davies, K. E. Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. *Mol. Ther.* **2010**, *18*, 198–205.
- 65 Koppelhus, U.; Shiraiishi, T.; Zachar, V.; Pankratova, S.; Nielsen, P. E. Improved cellular activity of antisense peptide nucleic acids by conjugation to a cationic peptide-lipid (CatLip) domain. *Bioconjugate Chem.* **2008**, *19*, 1526–1534.
- 66 Nakase, I.; Akita, H.; Kogure, K.; Graslund, A.; Langel, U.; Harashima, H.; Futaki, S. Efficient Intracellular Delivery of Nucleic Acid Pharmaceuticals Using Cell-Penetrating Peptides. *Acc. Chem. Res.* **2011**.